Published mark

LEXICON PHARMACEUTICALS, INC.

NASDAQ: LXRX. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:481f3104-140b-4121-9055-f6803dba7825
SEC CIK
0001062822
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 11, 2026
Newest evidence
Mar 16, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Michael S. Exton, Ph.D.Since Mar 5, 2026
Chair
Not published
Independent
3 / 77 directors published
Published claims
243 distinct sources
Evidence records
110 pinned
Source conflicts
0None open

Built from 3 distinct sources and 11 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

GC CHANGED

Brian T. Crum executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.

EffectiveEffective Mar 5, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Senior Vice President and General CounselBrian T. CrumMar 2026currentSource reportedE3
Senior Vice President and Chief Medical OfficerCraig B. Granowitz, M.D., Ph.D.Mar 2026currentSource reportedE4
Senior Vice President, Investor Relations and Corporate CommunicationsLisa M. DeFrancescoMar 2026currentSource reportedE5
Chief Executive Officer and DirectorMichael S. Exton, Ph.D.Mar 2026currentSource reportedE6
Senior Vice President, Partnerships and Corporate StrategyRachel Y. MartensMar 2026currentSource reportedE7
Senior Vice President and Chief Financial OfficerScott M. CoianteMar 2026currentSource reportedE8
Senior Vice President, DiscoverySuma Gopinathan, M.S., Ph.D.Mar 2026currentSource reportedE9
Senior Vice President, Human ResourcesWendy E. McDermottMar 2026currentSource reportedE10

Board of directors

Evidence

7 directors published. 3 of 7 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Christopher J. SobeckiNot independent2007None publishedSource reportedE2
Diane E. SullivanIndependent2023AuditSource reportedE2
Ivan H. CheungIndependent2024AuditSource reportedE2
Michael S. Exton, Ph.D.Not independent2024None publishedSource reportedE2
Philippe J. AmouyalNot independent2007CompensationSource reportedE2
Raymond DebbaneNot independent2007None publishedSource reportedE2
Samuel L. Barker, Ph.D.Independent2000None publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditNot publishedDiane E. Sullivan, Ivan H. CheungNot described in the published record
CompensationNot publishedPhilippe J. AmouyalNot described in the published record
Committee RecordAudit: Chair not stated; Members Diane E. Sullivan; Ivan H. Cheung
Source reportedE11
company:481f3104-140b-4121-9055-f6803dba7825:committee_record:20
Committee AppointmentDiane E. Sullivan: member, Audit
Source reportedE11
company:481f3104-140b-4121-9055-f6803dba7825:committee_appointment:21
Committee AppointmentIvan H. Cheung: member, Audit
Source reportedE11
company:481f3104-140b-4121-9055-f6803dba7825:committee_appointment:22
Committee RecordCompensation: Chair not stated; Members Philippe J. Amouyal
Source reportedE11
company:481f3104-140b-4121-9055-f6803dba7825:committee_record:23
Committee AppointmentPhilippe J. Amouyal: member, Compensation
Source reportedE11
company:481f3104-140b-4121-9055-f6803dba7825:committee_appointment:24

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerMichael S. Exton, Ph.D., Chief Executive Officer and Director, from Mar 5, 2026
Source reportedE6
company:481f3104-140b-4121-9055-f6803dba7825:leadership_role:15
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingLXRX (NASDAQ)
Source reportedE1
company:481f3104-140b-4121-9055-f6803dba7825:security_listing:25
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 12, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameLEXICON PHARMACEUTICALS, INC.
Source reportedE1
company:481f3104-140b-4121-9055-f6803dba7825:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:481f3104-140b-4121-9055-f6803dba7825:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
11 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 11, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    LEXICON PHARMACEUTICALS, INC. DEF 14A 2026-03-16
    sec proxy. Published Mar 16, 2026. Retrieved Apr 25, 2026. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    LXRX 10-K executive officers
    sec filing. Published Mar 5, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  11. E11
    Audit
    board_seats. board seats. Cited by 5 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 11, 2026
  • Brian T. Crum executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Craig B. Granowitz, M.D., Ph.D. executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Lisa M. DeFrancesco executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Michael S. Exton, Ph.D. executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Rachel Y. Martens executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Scott M. Coiante executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Suma Gopinathan, M.S., Ph.D. executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Wendy E. McDermott executive of LEXICON PHARMACEUTICALS, INC., effective 2026-03-05.
  • Ivan H. Cheung seat on LEXICON PHARMACEUTICALS, INC., effective 2024-01-01.
  • Michael S. Exton, Ph.D. seat on LEXICON PHARMACEUTICALS, INC., effective 2024-01-01.
  • Diane E. Sullivan seat on LEXICON PHARMACEUTICALS, INC., effective 2023-01-01.
  • Diane E. Sullivan member of Audit, effective 2023-01-01.
  • Christopher J. Sobecki seat on LEXICON PHARMACEUTICALS, INC., effective 2007-01-01.
  • Philippe J. Amouyal seat on LEXICON PHARMACEUTICALS, INC., effective 2007-01-01.
  • Raymond Debbane seat on LEXICON PHARMACEUTICALS, INC., effective 2007-01-01.
  • Philippe J. Amouyal member of Compensation, effective 2007-01-01.
  • Samuel L. Barker, Ph.D. seat on LEXICON PHARMACEUTICALS, INC., effective 2000-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:481f3104-140b-4121-9055-f6803dba7825, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/lexicon-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership8
  4. Board7
  5. Committees2
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people14
  17. Subject and corrections6
  18. Evidence11
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:481f3104-140b-4121-9055-f6803dba7825
  • Cite this recordLEXICON PHARMACEUTICALS, INC.
  • Copy canonical URLregistry.alpha.ac/companies/lexicon-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    LEXICON PHARMACEUTICALS, INC.Company
  • Brian T. CrumPerson
  • Craig B. Granowitz, M.D., Ph.D.Person
  • Lisa M. DeFrancescoPerson
  • Michael S. Exton, Ph.D.Person
  • Rachel Y. MartensPerson
  • Scott M. CoiantePerson
  • Suma Gopinathan, M.S., Ph.D.Person
  • Wendy E. McDermottPerson
  • Christopher J. SobeckiPerson
  • Diane E. SullivanPerson
  • Ivan H. CheungPerson
  • Philippe J. AmouyalPerson
  • Raymond DebbanePerson
  • Samuel L. Barker, Ph.D.Person
  • Sections
    OverviewLEXICON PHARMACEUTICALS, INC.
  • MonitoringLEXICON PHARMACEUTICALS, INC.
  • LeadershipLEXICON PHARMACEUTICALS, INC.
  • BoardLEXICON PHARMACEUTICALS, INC.
  • CommitteesLEXICON PHARMACEUTICALS, INC.
  • Control and votingLEXICON PHARMACEUTICALS, INC.
  • Authority to actLEXICON PHARMACEUTICALS, INC.
  • FinancialsLEXICON PHARMACEUTICALS, INC.
  • GovernanceLEXICON PHARMACEUTICALS, INC.
  • RiskLEXICON PHARMACEUTICALS, INC.
  • AI oversightLEXICON PHARMACEUTICALS, INC.
  • LegalLEXICON PHARMACEUTICALS, INC.
  • CompensationLEXICON PHARMACEUTICALS, INC.
  • Other published claimsLEXICON PHARMACEUTICALS, INC.
  • Coverage gapsLEXICON PHARMACEUTICALS, INC.
  • Linked peopleLEXICON PHARMACEUTICALS, INC.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.